MARÍA PURIFICACIÓN
MARTÍNEZ DEL PRADO
Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre, BrasilPublications en collaboration avec des chercheurs de Pontifícia Universidade Católica do Rio Grande do Sul (1)
2017
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700